Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
27.49 USD | +4.60% | +6.67% | +140.13% |
11/04 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
03/04 | Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+140.13% | 314M | |
+2.96% | 108B | |
+10.32% | 105B | |
+1.57% | 23.46B | |
-12.45% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.54% | 17.19B | |
+6.08% | 13.99B | |
+37.31% | 12.53B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Baird Downgrades Homology Medicines to Neutral From Outperform, Adjusts Price Target to $1.50 From $9